Avalo Therapeutics’ (AVTX) Neutral Rating Reaffirmed at HC Wainwright

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports.

AVTX has been the subject of several other research reports. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday. Finally, BTIG Research assumed coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $35.33.

Avalo Therapeutics Trading Down 6.8 %

Shares of AVTX opened at $7.66 on Thursday. Avalo Therapeutics has a 12 month low of $4.60 and a 12 month high of $34.46. The stock has a fifty day moving average price of $7.45 and a 200-day moving average price of $9.11.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Ikarian Capital LLC grew its position in Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after purchasing an additional 915,629 shares during the period. RA Capital Management L.P. acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $9,186,000. Geode Capital Management LLC grew its position in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after purchasing an additional 94,742 shares during the period. Bank of Montreal Can acquired a new stake in Avalo Therapeutics during the 4th quarter worth about $446,000. Finally, Walleye Capital LLC acquired a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $145,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.